Evidence map›Paper›PMID 35477804›Full record

ArticleMedical oncology (Northwood, London, England)2022

Optimized flow cytometric detection of transient receptor potential vanilloid-1 (TRPV1) in human hematological malignancies.

Sofia A Omari, Dominic P Geraghty, Alhossain A Khalafallah, Pooja Venkat, Yvette M Shegog, Scott J Ragg, Charles E de Bock, Murray J Adams

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sofia A OmariSchool of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia. somari@ccia.org.au.ORCID http://orcid.org/0000-0003-0345-5601
Dominic P GeraghtySchool of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia.
Alhossain A KhalafallahSchool of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia.
Pooja VenkatChildren's Cancer Institute, School of Women's and Children's Health, Lowy Cancer Centre, University of New South Wales (UNSW), Sydney, NSW, Australia.
Yvette M ShegogSchool of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia.
Scott J RaggPathology Department, Royal Hobart Hospital, 48 Liverpool Street, Hobart, TAS, 7000, Australia.
Charles E de BockChildren's Cancer Institute, School of Women's and Children's Health, Lowy Cancer Centre, University of New South Wales (UNSW), Sydney, NSW, Australia.
Murray J AdamsSchool of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia.
University of Tasmania · AUCancer Institute of New South Wales · AURoyal Hobart Hospital · AU

Funding

Clifford Craig Foundation G0018836
6 · The paper itself

Abstract

The ectopic overexpression of transient receptor potential vanilloid-1 (TRPV1) has been detected in numerous solid cancers, including breast, prostate, pancreatic, and tongue epithelium cancer. However, the expression of TRPV1 in hematological malignancies remains unknown. Here we show through in silico analysis that elevated TRPV1 mRNA expression occurs in a range of hematological malignancies and presents an optimized flow cytometry method to rapidly assess TRPV1 protein expression for both cell lines and primary patient samples. Three anti-TRPV1 antibodies were evaluated for intracellular TRPV1 detection using flow cytometry resulting in an optimized protocol for the evaluation of TRPV1 in hematological malignant cell lines and patients' peripheral blood mononuclear cells (PBMC). Overexpression of TRPV1 was observed in THP-1 (acute monocytic leukemia) and U266B1 (multiple myeloma, MM), but not U937 (histiocytic lymphoma) compared to healthy PBMC. TRPV1 was also detected in all 49 patients including B-cell non-Hodgkin's lymphoma (B-NHL), MM, and others and 20 healthy controls. TRPV1 expression was increased in 8% of patients (MM = 2, B-NHL = 2). In conclusion, we provide an optimized flow cytometry method for routine expression analysis of clinical samples and show that TRPV1 is increased in a subset of patients with hematological malignancies.

Indexed as

Antineoplastic AgentsHematologic NeoplasmsTongue NeoplasmsChildFlow CytometryHumansLeukocytes, MononuclearMaleProstateTRPV Cation ChannelsAntineoplastic AgentsTRPV1 protein, humanTRPV Cation ChannelsFlow cytometryHematological malignanciesLeukemiaRNA-seqTransient receptor potential vanilloid-1 (TRPV1)Western blotting

Identifiers

PMID35477804
PMCPMC9046313
OpenAlexW4226479618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.